The type III TGF-β receptor suppresses breast cancer progression

Mei Dong, Tam How, Kellye C. Kirkbride, Kelly J. Gordon, Jason D. Lee, Nadine Hempel, Patrick Kelly, Benjamin J. Moeller, Jeffrey R. Marks, Gerard C. Blobe

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

The TGF-β signaling pathway has a complex role in regulating mammary carcinogenesis. Here we demonstrate that the type III TGF-β receptor (TβRIII, or betaglycan), a ubiquitously expressed TGF-β coreceptor, regulated breast cancer progression and metastasis. Most human breast cancers lost TβRIII expression, with loss of heterozygosity of the TGFBR3 gene locus correlating with decreased TβRIII expression. TβRIII expression decreased during breast cancer progression, and low TβRIII levels predicted decreased recurrence-free survival in breast cancer patients. Restoring TβRIII expression in breast cancer cells dramatically inhibited tumor invasiveness in vitro and tumor invasion, angiogenesis, and metastasis in vivo. TβRIII appeared to inhibit tumor invasion by undergoing ectodomain shedding and producing soluble TβRIII, which binds and sequesters TGF-β to decrease TGF-β signaling and reduce breast cancer cell invasion and tumor-induced angiogenesis. Our results indicate that loss of TβRIII through allelic imbalance is a frequent genetic event during human breast cancer development that increases metastatic potential.

Original languageEnglish (US)
Pages (from-to)206-217
Number of pages12
JournalJournal of Clinical Investigation
Volume117
Issue number1
DOIs
StatePublished - Jan 4 2007

Fingerprint

Breast Neoplasms
Neoplasms
Allelic Imbalance
Neoplasm Metastasis
Loss of Heterozygosity
Carcinogenesis
Breast
Recurrence
Survival
Genes
betaglycan

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Dong, M., How, T., Kirkbride, K. C., Gordon, K. J., Lee, J. D., Hempel, N., ... Blobe, G. C. (2007). The type III TGF-β receptor suppresses breast cancer progression. Journal of Clinical Investigation, 117(1), 206-217. https://doi.org/10.1172/JCI29293
Dong, Mei ; How, Tam ; Kirkbride, Kellye C. ; Gordon, Kelly J. ; Lee, Jason D. ; Hempel, Nadine ; Kelly, Patrick ; Moeller, Benjamin J. ; Marks, Jeffrey R. ; Blobe, Gerard C. / The type III TGF-β receptor suppresses breast cancer progression. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 1. pp. 206-217.
@article{01fc8edf54f0471dbc7b2602007b506d,
title = "The type III TGF-β receptor suppresses breast cancer progression",
abstract = "The TGF-β signaling pathway has a complex role in regulating mammary carcinogenesis. Here we demonstrate that the type III TGF-β receptor (TβRIII, or betaglycan), a ubiquitously expressed TGF-β coreceptor, regulated breast cancer progression and metastasis. Most human breast cancers lost TβRIII expression, with loss of heterozygosity of the TGFBR3 gene locus correlating with decreased TβRIII expression. TβRIII expression decreased during breast cancer progression, and low TβRIII levels predicted decreased recurrence-free survival in breast cancer patients. Restoring TβRIII expression in breast cancer cells dramatically inhibited tumor invasiveness in vitro and tumor invasion, angiogenesis, and metastasis in vivo. TβRIII appeared to inhibit tumor invasion by undergoing ectodomain shedding and producing soluble TβRIII, which binds and sequesters TGF-β to decrease TGF-β signaling and reduce breast cancer cell invasion and tumor-induced angiogenesis. Our results indicate that loss of TβRIII through allelic imbalance is a frequent genetic event during human breast cancer development that increases metastatic potential.",
author = "Mei Dong and Tam How and Kirkbride, {Kellye C.} and Gordon, {Kelly J.} and Lee, {Jason D.} and Nadine Hempel and Patrick Kelly and Moeller, {Benjamin J.} and Marks, {Jeffrey R.} and Blobe, {Gerard C.}",
year = "2007",
month = "1",
day = "4",
doi = "10.1172/JCI29293",
language = "English (US)",
volume = "117",
pages = "206--217",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

Dong, M, How, T, Kirkbride, KC, Gordon, KJ, Lee, JD, Hempel, N, Kelly, P, Moeller, BJ, Marks, JR & Blobe, GC 2007, 'The type III TGF-β receptor suppresses breast cancer progression', Journal of Clinical Investigation, vol. 117, no. 1, pp. 206-217. https://doi.org/10.1172/JCI29293

The type III TGF-β receptor suppresses breast cancer progression. / Dong, Mei; How, Tam; Kirkbride, Kellye C.; Gordon, Kelly J.; Lee, Jason D.; Hempel, Nadine; Kelly, Patrick; Moeller, Benjamin J.; Marks, Jeffrey R.; Blobe, Gerard C.

In: Journal of Clinical Investigation, Vol. 117, No. 1, 04.01.2007, p. 206-217.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The type III TGF-β receptor suppresses breast cancer progression

AU - Dong, Mei

AU - How, Tam

AU - Kirkbride, Kellye C.

AU - Gordon, Kelly J.

AU - Lee, Jason D.

AU - Hempel, Nadine

AU - Kelly, Patrick

AU - Moeller, Benjamin J.

AU - Marks, Jeffrey R.

AU - Blobe, Gerard C.

PY - 2007/1/4

Y1 - 2007/1/4

N2 - The TGF-β signaling pathway has a complex role in regulating mammary carcinogenesis. Here we demonstrate that the type III TGF-β receptor (TβRIII, or betaglycan), a ubiquitously expressed TGF-β coreceptor, regulated breast cancer progression and metastasis. Most human breast cancers lost TβRIII expression, with loss of heterozygosity of the TGFBR3 gene locus correlating with decreased TβRIII expression. TβRIII expression decreased during breast cancer progression, and low TβRIII levels predicted decreased recurrence-free survival in breast cancer patients. Restoring TβRIII expression in breast cancer cells dramatically inhibited tumor invasiveness in vitro and tumor invasion, angiogenesis, and metastasis in vivo. TβRIII appeared to inhibit tumor invasion by undergoing ectodomain shedding and producing soluble TβRIII, which binds and sequesters TGF-β to decrease TGF-β signaling and reduce breast cancer cell invasion and tumor-induced angiogenesis. Our results indicate that loss of TβRIII through allelic imbalance is a frequent genetic event during human breast cancer development that increases metastatic potential.

AB - The TGF-β signaling pathway has a complex role in regulating mammary carcinogenesis. Here we demonstrate that the type III TGF-β receptor (TβRIII, or betaglycan), a ubiquitously expressed TGF-β coreceptor, regulated breast cancer progression and metastasis. Most human breast cancers lost TβRIII expression, with loss of heterozygosity of the TGFBR3 gene locus correlating with decreased TβRIII expression. TβRIII expression decreased during breast cancer progression, and low TβRIII levels predicted decreased recurrence-free survival in breast cancer patients. Restoring TβRIII expression in breast cancer cells dramatically inhibited tumor invasiveness in vitro and tumor invasion, angiogenesis, and metastasis in vivo. TβRIII appeared to inhibit tumor invasion by undergoing ectodomain shedding and producing soluble TβRIII, which binds and sequesters TGF-β to decrease TGF-β signaling and reduce breast cancer cell invasion and tumor-induced angiogenesis. Our results indicate that loss of TβRIII through allelic imbalance is a frequent genetic event during human breast cancer development that increases metastatic potential.

UR - http://www.scopus.com/inward/record.url?scp=33845979811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845979811&partnerID=8YFLogxK

U2 - 10.1172/JCI29293

DO - 10.1172/JCI29293

M3 - Article

VL - 117

SP - 206

EP - 217

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -